ACADIA Pharmaceuticals Inc. Reports Recent Stock Performance

ACADIA Pharmaceuticals Inc., a biopharmaceutical company based in San Diego, United States, has recently seen notable activity in its stock performance. The company, which specializes in the discovery, development, and commercialization of small molecule drugs for central nervous system disorders, is listed on the Nasdaq stock exchange. As of May 14, 2025, ACADIA’s stock closed at $17.6.

The company’s stock has experienced fluctuations over the past year, with a 52-week high of $20.68 recorded on February 20, 2025, and a 52-week low of $13.4 on April 8, 2025. These movements reflect the dynamic nature of the biotechnology sector, where companies like ACADIA are at the forefront of developing treatments for complex conditions such as Parkinson’s disease, schizophrenia, neuropathic pain, and glaucoma.

ACADIA Pharmaceuticals Inc. has a market capitalization of $2.44 billion, indicating its significant presence in the health care sector. The company’s price-to-earnings ratio stands at 10.73, which provides investors with insight into its valuation relative to its earnings.

Founded with an Initial Public Offering (IPO) on May 27, 2004, ACADIA has grown to become a key player in the biotechnology industry. The company’s focus on addressing induced dysfunction in various central nervous system disorders underscores its commitment to advancing medical treatments and improving patient outcomes.

For more information, ACADIA Pharmaceuticals Inc. maintains an online presence through its website, www.acadia-pharm.com , where stakeholders can find detailed information about its ongoing projects and corporate developments. As the company continues to innovate in the field of biopharmaceuticals, it remains a significant entity within the health care sector.